Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. OKYO.L Share Price
  4. OKYO.L Share Regulatory News
  5. ADS Program collapse

Pin to quick picksOKYO.L Regulatory News (OKYO)

OKYO.L Information
  • There is currently no data for OKYO

ADS Program collapse

19 May 2023 08:00

RNS Number : 9540Z
OKYO Pharma Limited
19 May 2023
 

 

OKYO PHARMA LIMITED

ADS Program collapse - Commencement of trading of new ordinary shares on The Nasdaq Capital Market

LONDON and NEW YORK, May 19, 2023 -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) hereby announces that following the implementation of the share capital consolidation and collapse of its ADS program, it is expected that new OKYO ordinary shares will be listed on The Nasdaq Capital Market with effect from the opening of business in New York on Monday May, 22, 2023.

OKYO has been listed on The Nasdaq Capital Market via an ADS since May 17 2022. OYKO announced its intention to delist from the London Stock Exchange plc on April 2, 2023 and on May 3, 2023 shareholders passed the necessary resolutions to consolidate its existing ordinary shares by a 65 into 1 reverse split (thereby matching the current ADS ratio of 65 ordinary shares comprised in each ADS). Each new OKYO ordinary share will accordingly represent 65 of the old ordinary shares and be equal to one ADS.

The CUSIP for the new OKYO ordinary shares is G6724L116 and the ISIN is GG00BMFG5F62.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAKSPFSNDEFA
1234567
Date   Source Headline
7th Sep 20221:30 pmRNSResult of AGM
30th Aug 20227:00 amRNSQ4 '22 IND planned followed by P2 with AmbioPharm
19th Aug 20227:00 amRNSNotice of AGM
18th Aug 20222:06 pmRNSSecond Price Monitoring Extn
18th Aug 20222:00 pmRNSPrice Monitoring Extension
16th Aug 20227:00 amRNSAnnual Financial Report
9th Jun 20227:08 amRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSDirector/PDMR Shareholding
19th May 20224:01 pmRNSClosing of Offering
18th May 202210:10 amRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSOKYO Announces Pricing of IPO of ADSs in the U.S.
27th Apr 20227:00 amRNSUpcoming Presentations at Ophthalmic Conference
7th Mar 20227:00 amRNSAdditional Listing
23rd Feb 20227:00 amRNSPatent issued: to treat ocular neuropathic pain
21st Feb 20225:00 pmRNSCLN Conversion, exercise of Warrants, equity issue
15th Feb 20227:00 amRNSSuccessful Pre-IND Meeting with the FDA on OK-101
1st Feb 20227:00 amRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSHalf-year Report
14th Dec 20217:00 amRNSU.S. Patent issued for use of OK-101 to treat DED
13th Dec 20217:00 amRNSOK-101:Anti-inflammatory & Pain-Reducing Potential
6th Dec 20217:00 amRNSIND filing Q3 2022 and Phase 2 initiation Q4 2022
1st Dec 20217:00 amRNSDirectorate Change
19th Oct 20214:41 pmRNSSecond Price Monitoring Extn
19th Oct 20214:35 pmRNSPrice Monitoring Extension
19th Oct 20212:05 pmRNSSecond Price Monitoring Extn
19th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Sep 202112:06 pmRNSResult of AGM
9th Sep 20217:00 amRNSNotice of AGM
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202111:32 amRNSAnnual Financial Report
29th Jun 20217:00 amRNSResearch Update
17th Jun 20213:58 pmRNSDirectorate Change
12th May 20217:00 amRNSHolding(s) in Company
7th May 202110:07 amRNSAdditional Listing
5th May 202111:53 amRNSPublication of a Prospectus
28th Apr 20217:00 amRNSPositive Data in an Animal Model using OK-201
29th Mar 20217:00 amRNSAppointment of Chief Scientific Officer
3rd Mar 20217:00 amRNSIssue of Equity
1st Mar 20217:00 amRNSIssue of Equity
23rd Feb 20217:00 amRNSPatent for treating Ocular Pain and Inflammation
19th Jan 20217:00 amRNSFiling patent application for the use of Chemerin
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:37 pmRNSPrice Monitoring Extension
14th Jan 20212:05 pmRNSSecond Price Monitoring Extn
14th Jan 20212:00 pmRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDirectorate Change
30th Nov 20207:00 amRNSHalf-year Report
1234567

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
CGT
Capital Gearing Trust
LSE
-0.19%
CEMA
Ishr Em Asia
LSE
-4.65%
0XVE
Be Semiconduct
LSE
-3.44%
WEIR
Weir Group
LSE
-2.71%
RWI
Renewi Plc
LSE
0.00%
Trending
ECO
Eco (atlantic)
LSE
-2.03%
ALRT
Defence Holdings
LSE
19.05%
IMM
Immupharma
LSE
-2.26%
BA.
BAE Systems
LSE
0.76%
SBTX
Skinbiotherap.
LSE
0.00%